ArticleScientific reports2025
Polydatin exerts therapeutic effects on myelodysplastic syndrome by inhibiting the protein expression of oncogenes via hypermethylation in vitro.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
DNA methylation plays a critical role in myelodysplastic syndrome (MDS). Here, we aimed to observe the effects of polydatin (PD) on DNA methylation in MDS cells on a genome-wide scale and explore the underlying mechanisms, providing new evidence for PD as a novel hypermethylation agent. We used the Gene Expression Omnibus (GEO) online database to evaluate the DNA methylation characteristics of MDS patients. A Human Methylation 850 K BeadChip was used to evaluate the effects of PD on DNA methylation in SKM-1 cells. Western blotting (WB) was used to observe changes in the expression of related proteins. Cytoscape was used to determine the key genes that were hypermethylated by PD. The therapeutic effects were evaluated using flow cytometry experiment and a cell counting kit-8 (CCK-8) assay in vitro. Data from the GEO online database revealed that aberrant gene hypomethylation plays an important role in MDS. In MDS cells, 448 genes (71.91%) were hypermethylated following PD treatment. These hypermethylated genes are related to cancer-related signaling pathways. Moreover, key hypermethylated genes, including PIK3CA, ITPR3 and SPOPL, were identified, and these three genes are all oncogenes. Most importantly, PD decreased the protein expression of the above three oncogenes. Finally, we found that PD could inhibit the proliferation of MDS cells, arrest them in the S phase and induce their apoptosis. Our findings demonstrated that PD has therapeutic effects on MDS by inhibiting the protein expression of oncogenes via hypermethylation in vitro, indicating that PD may be a novel hypermethylation agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.